Text Size

Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2003 by Johns Hopkins University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00244803
First received: October 25, 2005
Last updated: NA
Last verified: September 2003
History: No changes posted
  Purpose

The purpose of this study is to learn whether HIV-infected patients have blood abnormalities which could lead to heart attack or stroke, and to find out what factors may contribute to these abnormalities.


Condition
Human Immunodeficiency Virus

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: Redistribution and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Johns Hopkins University:

Estimated Enrollment: 101
Study Start Date: January 2005
Detailed Description:

This research is being done to learn whether HIV-infected patients have abnormalities in their blood vessels that could eventually lead to heart attack or stroke (atherosclerosis), in how fat is distributed in their body and in how their body handles fat and sugars. If there are abnormalities, this study will also try to find out what factors may contribute to those abnormalitites.

People who participated in FRAM 1 may join FRAM 2.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:18-65 years old, previous FRAM 1 participant, HIV positive -

Exclusion Criteria:Artificial knee or hip replacement or Harrington rod.Metal objects in the body.Pregnancy. Breastfeeding or less than 3 months after breastfeeding.Weight more than 300 pounds.On insulin, pancreatic enzymes, or thioridazine.

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00244803

Locations
United States, Maryland
Johns Hopkins University, The Clinical Trials Unit
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Johns Hopkins University
National Institutes of Health (NIH)
Investigators
Principal Investigator: Joseph Cofrancesco Jr., M.D. Johns Hopkins University
  More Information

No publications provided by Johns Hopkins University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00244803     History of Changes
Other Study ID Numbers: 03-07-02-01
Study First Received: October 25, 2005
Last Updated: October 25, 2005
Health Authority: United States: Institutional Review Board

Keywords provided by Johns Hopkins University:
Human Immunodeficiency Virus
FRAM 1

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
 Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 21, 2013